drugset / Trial / NCT05731050

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05731050

Phase 2 Not yet recruiting 6 enrolled NovelMed Therapeutics
NaSequentialOpen-labelTreatment

Summary

The proposed study, NM8074-PNH-101, is a phase II, open-label, multi-dose, unicenter trial to evaluate the safety and efficacy of NM8074 in Soliris-treated PNH subjects.

Timeline

Start
2026-06
Primary completion
2027-09
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RUXOPRUBART Monoclonal antibody 15 mg/kg Intravenous